Equities analysts expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will post ($0.92) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Protagonist Therapeutics’ earnings. Protagonist Therapeutics posted earnings per share of ($19.07) during the same quarter last year, which suggests a positive year over year growth rate of 95.2%. The business is expected to report its next quarterly earnings report on Thursday, September 21st.
On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($3.74) per share for the current financial year. For the next year, analysts forecast that the company will report earnings of ($3.44) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.23.
A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 10th. BMO Capital Markets lifted their price objective on Protagonist Therapeutics from $34.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, May 31st.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Protagonist Therapeutics, Inc. (PTGX) to Post -$0.92 Earnings Per Share” was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/markets/2285741/zacks-analysts-anticipate-protagonist-therapeutics-inc-ptgx-to-post-0-92-earnings-per-share.html.
Several hedge funds and other institutional investors have recently made changes to their positions in PTGX. Teachers Advisors LLC increased its position in shares of Protagonist Therapeutics by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 9,461 shares of the company’s stock valued at $208,000 after buying an additional 1,424 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Protagonist Therapeutics by 15.1% in the first quarter. Bank of New York Mellon Corp now owns 26,148 shares of the company’s stock valued at $335,000 after buying an additional 3,433 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Protagonist Therapeutics by 1.9% in the first quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock valued at $1,296,000 after buying an additional 1,850 shares during the last quarter. State Street Corp increased its position in shares of Protagonist Therapeutics by 50.8% in the fourth quarter. State Street Corp now owns 92,163 shares of the company’s stock valued at $2,028,000 after buying an additional 31,042 shares during the last quarter. Finally, FMR LLC increased its position in shares of Protagonist Therapeutics by 0.4% in the first quarter. FMR LLC now owns 2,518,198 shares of the company’s stock valued at $32,258,000 after buying an additional 11,031 shares during the last quarter. 47.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of Protagonist Therapeutics (NASDAQ:PTGX) traded up 0.47% during mid-day trading on Friday, hitting $12.75. The company had a trading volume of 26,218 shares. Protagonist Therapeutics has a 12-month low of $8.00 and a 12-month high of $26.36. The firm’s market cap is $214.91 million. The firm’s 50 day moving average is $10.80 and its 200-day moving average is $14.24.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285741/zacks-analysts-anticipate-protagonist-therapeutics-inc-ptgx-to-post-0-92-earnings-per-share.html
Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.